Trial Profile
A study to investigate dose of Imatinib Mesylate based on body surface area in patients with chronic phase Chronic myelogenous leukemia (CML).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 07 Dec 2015
Price :
$35
*
At a glance
- Drugs Imatinib (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions
- 07 Dec 2015 New trial record